Doctor's Notes

Topical Eczema Treatment Satisfaction: What 267 US Patients and Caregivers Said

AI-created editorial illustration for “eczema topical treatment satisfaction 267 us survey”; Dr. Arsy #003 was not the study product.

Editorial image disclosure: the featured image is AI-created. Dr. Arsy #003 was not the study product.

The 2025 US survey included 267 adolescents and adults with moderate-to-severe atopic dermatitis who were using topical therapy alone or alongside advanced systemic treatment. 1234

Key findings and limitations

Sixty-eight percent reported disliking how topical treatment felt on the skin. Agreement between clinicians and patients/caregivers was only fair to moderate for satisfaction and some instruction domains, with weaker concordance in severe disease and combined-therapy groups. 5678

What the broader evidence adds

Guidelines, burden studies and preference research answer different questions. Cohorts and surveys describe patterns; randomized trials are needed for treatment effects; patient priorities still matter when options have different routes, monitoring and tradeoffs. 910111213

Practical interpretation

Vehicle, greasiness, stinging, time, clothing transfer, amount and frequency can determine whether a theoretically effective plan is usable. Ask the patient to demonstrate application and describe what happens on a real weekday, not an ideal one. 14151617

Safety boundary

Do not discontinue prescription treatment solely because of texture without discussing alternatives. Burning, swelling, hives, infection or unexpected worsening needs medical advice. Findings from one population should not be transferred automatically to every baby, child or adult. 18192021

Where #003 fits

Dr. Arsy Moisturizer #003, 4 oz is an optional cosmetic moisturizer for dry, sensitive and eczema-prone skin. It was not evaluated in the cited study and is not claimed here to treat, cure or prevent eczema or another condition.

Related Dr. Arsy research guides

References

  1. Skin microbiome resilience during topical treatment
  2. Pediatric dupilumab response across racial and ethnic groups
  3. Burden of mild and moderate atopic dermatitis in US adults
  4. Caregiver-reported access to mental health services
  5. Topical therapy experience, satisfaction and communication
  6. International patient and caregiver education-needs survey
  7. Type 2 diabetes risk in atopic dermatitis: age-stratified TriNetX analysis
  8. Adult eczema, oral health and oral dysbiosis case-control study
  9. Disease control, perceived risk and treatment decisions
  10. Pediatric, young-adult and caregiver treatment goals
  11. Preferences in atopic dermatitis: systematic review
  12. Adult AAD focused guideline update
  13. Pediatric AAD management guideline
  14. Pediatric prevention and comorbidity guideline
  15. Mental-health burden in atopic dermatitis
  16. Atopic dermatitis and sleep disorders: UK Biobank
  17. Patient treatment needs in TREATgermany
  18. Online versus in-person eczema care randomized trial
  19. Infectious complications of atopic dermatitis update
  20. 71-outcome UK eczema cohort program
  21. US Optum disease-event cohort

← Back to Doctor's Notes